Navigation Links
Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Date:10/25/2011

p>- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 8

1.2 List of Figures 12

2 CNS Disorder Therapeutic Market to 2017 - Introduction 15

2.1 GBI Research Report Guidance 15

3 CNS Disorder Therapeutic Market to 2017 - Global Market Overview 16

3.1 Introduction 16

3.2 Revenue 17

3.2.1 Generic Share 18

3.2.2 Annual Cost of Treatment 19

3.3 Top CNS Drug Products 20

3.3.1 Seroquel (IR/XR) (quetiapine fumarate) 20

3.3.2 Zyprexa (olanzapine) 20

3.3.3 Cymbalta (duloxetine Hcl) 21

3.3.4 Copaxone (glatiramer acetate) 21

3.3.5 Lyrica (pregabalin) 22

3.3.6 Abilify (aripiprazole) 22

3.3.7 Avonex (Interferon beta-1a) 23

3.3.8 Rebif (interferon beta-1a) 23

3.3.9 Effexor (venlafaxine) 23

3.3.10 Betaferon /Betaseron (Interferon beta-1b) 24

4 CNS Disorder Therapeutic Market to 2017 - Geographical Landscape 25

4.1 Revenue Analysis by Geography 25

4.2 The US 26

4.2.1 Revenue 26

4.2.2 Annual Cost of Treatment 27

4.3 Top Five Countries of Europe 28

4.3.1 Revenue 28

4.3.2 Annual Cost of Treatment 30

4.4 Japan 31

4.4.1 Revenue 31

4.4.2 Annual Cost of Treatment 32

5 CNS Disorder Therapeutic Market to 2017 - Therapeutic Landscape 33

5.1 Alzheimer's Disease 33

5.1.1 Introduction 33

5.1.2 Revenue 35

5.1.3 Annual Cost of Treatment 39

5.1.4 Treatment Usage Patterns 40

5.2 Drivers and Restraints to Alzheimer's Disease Market 42

5.2.1 Drivers for Alzheimer's disease Market 42

5.2.2 Restraints for Alzheimer's disease Market 43'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Bioness Inc. Receives FDA Clearance and CE Mark for Its NESS H200 Wireless System for Hand Paralysis as a Result of Stroke and Other Central Nervous System Disorders
2. South and Central America Cardiovascular Devices Market Outlook to 2017
3. Carolinas HealthCare System (CHS) Contributes to First Childrens Burn Hospital in Central America
4. Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011
5. United Seating & Mobility Reaches Agreement to Acquire Central Kentucky Mobility
6. Reportlinker Adds South and Central America Dental Devices Market Outlook to 2017
7. Reportlinker Adds South and Central America Drug Delivery Devices Market Outlook to 2017
8. Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
9. Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
10. Reportlinker Adds Drug Delivery Devices Market Outlook in Russian Federation to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
11. Reportlinker Adds Drug Delivery Devices Market Outlook in China to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today ... ended June 28, 2014.  , Revenues were $10.6 ... $9.2 million in the 2013 second quarter and up sequentially ... for the first six months of 2014 were $20.9 million, ... of last year. , Gross margin for the quarter ...
(Date:7/31/2014)... Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical ... reported its financial results for the quarter ended June 30, ... 2014 to the same period of 2013: , Sales ... , t:slim Pump shipments grew 64 percent to 2,235 pumps ... June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... Inc. (the "Company") (Nasdaq: PCYC ) today reported ... 30, 2014. Financial Results for the Six Months ... for the quarter ended June 30, 2014 increased to $113.0 ... 2013 primarily due to IMBRUVICA ® (ibrutinib) net product ... the six months ended June 30, 2014 increased to $232.4 ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25
... SAN FRANCISCO , June 22 Jennerex, Inc., ... Gregory W. Schafer as senior vice president and chief financial ... planning, investor relations and treasury functions. , ... "Greg,s finance and operations experience in the ...
... BENTONVILLE, Ark. , June 22 Walmart (NYSE: ... today they,re teaming up to provide an affordable insulin option for people with ... Beginning in mid-September, Lilly,s ... pharmacies across the U.S. under the dual-branded name Humulin ® ReliOn ...
Cached Medicine Technology:Jennerex Appoints Gregory W. Schafer as Chief Financial Officer 2Jennerex Appoints Gregory W. Schafer as Chief Financial Officer 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 2Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 4Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 5
(Date:8/1/2014)... Lake City, UT (PRWEB) August 01, 2014 ... Medical Billing Experts, LLC (MBX) with the convergence ... Medical Professionals (BOSS), Salt Lake City, UT; Premier ... Six Seven Group (67G) of Charlotte, NC. Together ... some of the nation’s largest radiology group practices, ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 According to the ... is a comprehensive diet guide for women who want to ... list of protein rich foods and fat loss ... muscle mass. , Vkool writes in its review that this ... the truth about fat burning hormones and weight loss supplements. ...
(Date:8/1/2014)... The Journal of Neurosurgery is pleased ... the August issue entitled "Race Against the Clock: ... Hemorrhage." Authored by Peter Le Roux, MD, Charles ... and Alisa Schaefer, PhD, the 20-page supplement covers ... and methods in use for management of the ...
(Date:8/1/2014)... Millions of women suffer with lipedema, a ... some cases the arms, causing an abnormal accumulation of ... women in the U.S. alone are affected. With such ... embarrassment and discomfort caused by lipedema, it’s remarkable that ... that this is a disease,” says Dr. David Greuner, surgical ...
(Date:8/1/2014)... 2014 Register to join the webinar here: ... active years on record for life sciences investing. IPOs in ... 22 percent of all venture dollars spent in 2013. The ... valuations. , However, 2014 is proving more of a ... Silicon Valley Bank, while life sciences IPOs are losing steam, ...
Breaking Medicine News(10 mins):Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 2Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 3Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 3Health News:Management of anticoagulant-associated intracerebral hemorrhage 2Health News:Management of anticoagulant-associated intracerebral hemorrhage 3Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3
... Dr. ... , and is giving patients in Texas new reasons to smile. , ... (Vocus) August 24, 2009 -- Mark Sweeney, DDS knows cosmetic dentistry… ... is director of Austin Dental Spa , a practice devoted to turning visits to the ...
... , SEATTLE, Aug. 24 Cell Therapeutics, Inc. ... and Drug Administration (FDA) has accepted and has filed for review ... relapsed or refractory aggressive non-Hodgkin,s lymphoma (NHL). A Prescription Drug User ... the review of the pixantrone NDA by September 4th 2009. ...
... Mortality remains high among patients with pulmonary arterial hypertension ... that were designed to reduce mortality and increase the ... out of University of California San Francisco. ... of the American Journal of Respiratory and Critical ...
... of Idiopathic Pulmonary Fibrosis is not much better than ... survival rate is less than three years. But ... targeting of a novel gene utilizing genetic and pharmacologic ... and will be developed for future testing in humans. ...
... ... Washington D.C. is business owner John Wahlquist of eMedicalSystems, Bremerton, Washington state. Author of his ... choice to retire his product and migrate his medical practices over to a new generation ... ...
... FAYETTE COUNTY, Ga. , Aug. 22 Dominique Wilkins, NBA ... create awareness of the fact that seniors at risk for diabetes ... provider,s office. This is the core message of the Medicare ... in Georgia since 2007 and is co-chaired nationally by the American ...
Cached Medicine News:Health News:Austin Texas Cosmetic Dentist Celebrates 30 Years in Practice 2Health News:Austin Texas Cosmetic Dentist Celebrates 30 Years in Practice 3Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 2Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 3Health News:Still holding their breath: Mortality on lung transplant wait list remains high for some 2Health News:Still holding their breath: Mortality on lung transplant wait list remains high for some 3Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 3Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 2Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 3Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 4
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
... hinged knee brace provides maximum ... types of sports and activities. ... rubber pads to support medial ... buttress and hyperextension stop. 3/16" ...
Medicine Products: